CNBCLean R·
Big Pharma’s China deal spree grows with latest tie-up worth up to $7.8 billion
Western biopharma companies are increasingly turning to China to source innovation, as pharma's dreaded "patent cliff" draws closer.
Read at CNBC →
Business · 1 sources covering this
Big Pharma’s China deal spree grows with latest tie-up worth up to $7.8 billion
Western biopharma companies are increasingly turning to China to source innovation, as pharma's dreaded "patent cliff" draws closer.
Coverage spectrum
0 L · 0 C · 1 R
How 1 sources are covering this
Embed this bias spectrum on your site
Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.
<iframe src="https://statesidedaily.com/embed/cluster/e93d1b8c6ad60ce484d4d6605b6caa7d762f7335" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Big Pharma’s China deal spree grows with latest tie-up worth up to $7.8 billion"></iframe>
